

## **Supplementary material**

Bacharach J, Tatham A, Ferguson G, Belalcázar S, Thieme H, Goodkin ML, Chen MY, Guo Q, Liu J, Robinson MR, Bejarian M, Wirta DL; on behalf of the ARTEMIS 2 Study Group. Phase 3, randomized, 20-month study of the efficacy and safety of bimatoprost implant in patients with open-angle glaucoma and ocular hypertension (ARTEMIS 2). *Drugs*.

Author for correspondence: Jason Bacharach, MD; North Bay Eye Associates, Petaluma, CA, USA; Email: [jbacharach@northbayeye.com](mailto:jbacharach@northbayeye.com)

## Online Resource 5

### Ocular TEAEs in Study Eyes<sup>a</sup>

| TEAE                                 | n (%)                                   |                                         |                           |                               |
|--------------------------------------|-----------------------------------------|-----------------------------------------|---------------------------|-------------------------------|
|                                      | Bimatoprost<br>Implant 10 µg<br>(N=175) | Bimatoprost<br>Implant 15 µg<br>(N=176) | Timolol<br>BID<br>(N=173) | All Fellow<br>Eyes<br>(N=524) |
| Conjunctival hyperemia               | 48 (27.4)                               | 71 (40.3)                               | 19 (11.0)                 | 86 (16.4)                     |
| Foreign body sensation in eye        | 17 (9.7)                                | 18 (10.2)                               | 2 (1.2)                   | 17 (3.2)                      |
| Conjunctival hemorrhage              | 16 (9.1)                                | 14 (8.0)                                | 12 (6.9)                  | 22 (4.2)                      |
| Corneal endothelial cell loss        | 14 (8.0)                                | 45 (25.6)                               | 1 (0.6)                   | 4 (0.8)                       |
| Intraocular pressure increased       | 14 (8.0)                                | 17 (9.7)                                | 5 (2.9)                   | 18 (3.4)                      |
| Photophobia                          | 13 (7.4)                                | 13 (7.4)                                | 0                         | 13 (2.5)                      |
| Eye pain                             | 11 (6.3)                                | 21 (11.9)                               | 8 (4.6)                   | 16 (3.1)                      |
| Dry eye                              | 10 (5.7)                                | 16 (9.1)                                | 7 (4.0)                   | 31 (5.9)                      |
| Blepharitis                          | 9 (5.1)                                 | 7 (4.0)                                 | 5 (2.9)                   | 18 (3.4)                      |
| Eye irritation                       | 9 (5.1)                                 | 12 (6.8)                                | 7 (4.0)                   | 23 (4.4)                      |
| Vision blurred                       | 9 (5.1)                                 | 7 (4.0)                                 | 1 (0.6)                   | 11 (2.1)                      |
| Iritis                               | 8 (4.6)                                 | 9 (5.1)                                 | 0                         | 1 (0.2)                       |
| Punctate keratitis                   | 8 (4.6)                                 | 13 (7.4)                                | 7 (4.0)                   | 26 (5.0)                      |
| Anterior chamber cell                | 6 (3.4)                                 | 12 (6.8)                                | 1 (0.6)                   | 1 (0.2)                       |
| Corneal edema                        | 6 (3.4)                                 | 23 (13.1)                               | 0                         | 0                             |
| Lacrimation increased                | 6 (3.4)                                 | 9 (5.1)                                 | 1 (0.6)                   | 12 (2.3)                      |
| Aqueous humor leakage                | 5 (2.9)                                 | 1 (0.6)                                 | 0                         | 0                             |
| Conjunctivitis                       | 5 (2.9)                                 | 6 (3.4)                                 | 3 (1.7)                   | 10 (1.9)                      |
| Conjunctivitis allergic              | 5 (2.9)                                 | 3 (1.7)                                 | 2 (1.2)                   | 8 (1.5)                       |
| Iris hyperpigmentation               | 5 (2.9)                                 | 5 (2.8)                                 | 0                         | 1 (0.2)                       |
| Vitreous floaters                    | 5 (2.9)                                 | 1 (0.6)                                 | 2 (1.2)                   | 4 (0.8)                       |
| Erythema of eyelid                   | 4 (2.3)                                 | 3 (1.7)                                 | 1 (0.6)                   | 6 (1.1)                       |
| Iris adhesions                       | 4 (2.3)                                 | 3 (1.7)                                 | 0                         | 2 (0.4)                       |
| Anterior chamber flare               | 3 (1.7)                                 | 5 (2.8)                                 | 0                         | 0                             |
| Ocular discomfort                    | 3 (1.7)                                 | 11 (6.3)                                | 1 (0.6)                   | 4 (0.8)                       |
| Vitreous detachment                  | 3 (1.7)                                 | 4 (2.3)                                 | 1 (0.6)                   | 4 (0.8)                       |
| Anterior chamber<br>inflammation     | 2 (1.1)                                 | 4 (2.3)                                 | 0                         | 0                             |
| Corneal touch                        | 2 (1.1)                                 | 4 (2.3)                                 | 0                         | 0                             |
| Visual acuity reduced                | 2 (1.1)                                 | 5 (2.8)                                 | 0                         | 2 (0.4)                       |
| Keratitis                            | 1 (0.6)                                 | 4 (2.3)                                 | 3 (1.7)                   | 5 (1.0)                       |
| Vital dye staining cornea<br>present | 0                                       | 4 (2.3)                                 | 1 (0.6)                   | 2 (0.4)                       |
| Overall <sup>b</sup>                 | 109 (62.3)                              | 142 (80.7)                              | 83 (48.0)                 | 257 (49.0)                    |
| P value <sup>c</sup>                 | 0.007                                   | <0.001                                  | —                         | —                             |

*BID* twice daily, *TEAE* treatment-emergent adverse event

<sup>a</sup>All ocular TEAEs in study eyes that were reported in ≥2% of patients in any treatment group, regardless of relationship to treatment and time of onset, are listed

<sup>b</sup>Any ocular TEAE in the study eye

<sup>c</sup>P value for comparison of overall TEAE vs timolol (Chi-square test)